Expression Of MAGE-A1 Antigen In Nasopharyngeal Carcinoma And Non-Small Cell Lung Cancer

OBJECTIVE To predict the expression of cancer testis antigen (CTA) MAGE-A1 in human nasopharyngeal carcinoma (NPC) and non-small cell lung cancer (NSCLC). To provide some data for immunodiagnosis, immunotherapy of NPC and NSCLC.METHODS Using Enzyme immunohistochemistry method to detect the expression of MAGE-A1 antigen in 50 NPC patients and in 43 NSCLC patients (as well as their non-cancer tissues, including 10 non-cancer nasopharyngeal tissues and 6 non-cancer lung tissues). The results of expression and clinicopathologic parameters of the patients were analyzed with SPSS 13.0 statistic analysis software.RESULTS (1) Expression of MAGE-A1 was observed in 21 Cases respectively of 50 cases in NPC and 31 cases respectively of 43 cases in NSCLC; (2) The difference of the expression of MAGE-A1 between NPC and NSCLC is significant by statistic analysis (p<0.05). (3) The expression of MAGE-A1 in NPC and NSCLC was not correlated with sex, age, TNM grade and whether metastasized or not. CONCLUSION MAGE-A1 antigen may be a special antigen of NPC and NSCLC, which may be used as a target for immunodiagnosis and immunotherapy of NPC and NSCLC.